Clik here to view.
Prognostic Factors Associated With Severe COVID-19 in Cancer Patients
Certain factors may increase the risk of severe COVID-19 in cancer patients, according to research presented at ASCO Breakthrough 2023. Results from this single-center study suggested that high...
View ArticleClik here to view.
Specialized Care Needed for LGBTQ+ AYAs With Cancer
Adolescents and young adults (AYAs) with cancer who are sexual or gender minorities face unique challenges in the health care setting, according to research presented in a poster at ASCO Breakthrough...
View ArticleClik here to view.
Excessive Alcohol Consumption May Be Common in Cancer Patients, Survivors
(HealthDay News) — Alcohol consumption and risky drinking behaviors may be common among cancer survivors and cancer patients currently receiving treatment, according to a study published in JAMA...
View ArticleClik here to view.
Cancer Was Underdiagnosed in the First Year of the COVID-19 Pandemic
Cancer was underdiagnosed in the United States during the first year of the COVID-19 pandemic, according to research published in The Lancet Oncology. Researchers found that stage I cancer was more...
View ArticleClik here to view.
Less Than Half of Cancer Trials Had Results Reported Within 1 Year of Completion
In an analysis of more than 10,000 cancer clinical trials, less than half had results reported within 1 year of trial completion. Within 3 years, about 72% of trials had results reported, most commonly...
View ArticleClik here to view.
Industry-Sponsored Cancer Trials More Likely to Have Consent Documents...
Industry-sponsored cancer trials are more likely to have consent documents translated to languages other than English, according to research published in Nature. Researchers found that the odds of...
View ArticleClik here to view.
Systemic Therapies May Increase Risk of VTE in Patients With Cancer and COVID-19
Patients with cancer and COVID-19 may need close monitoring and personalized thromboprophylaxis due to an increased risk of venous thromboembolism (VTE), according to researchers. The researchers found...
View ArticleClik here to view.
Nilotinib Linked to Higher Risk of Diabetes, Hyperlipidemia in CML Patients
Patients with chronic myeloid leukemia (CML) who receive nilotinib instead of other tyrosine kinase inhibitors (TKIs) may have a greater risk of developing diabetes and hyperlipidemia, according to...
View ArticleClik here to view.
Deaths Among Cancer Patients Increased During the First 2 Years of the...
New research suggests that, during the first 2 years of the COVID-19 pandemic, there was a 4% increase in deaths among cancer patients in the United States. Deaths in patients with COVID-19 and cancer...
View ArticleClik here to view.
Cancer Survivors With Functional Disabilities Have Higher Health Care Costs
Cancer survivors with functional disabilities have higher health care usage and medical costs than survivors without disabilities, according to study results published in JNCI Cancer Spectrum. Costs...
View ArticleClik here to view.
Risk of Albuminuria Higher With Dasatinib Than With Other TKIs
(HealthDay News) — Patients with chronic myeloid leukemia (CML) have a higher risk of albuminuria if they receive dasatinib rather than other tyrosine kinase inhibitors (TKIs), according to a study...
View ArticleClik here to view.
Bosulif Approved for Pediatric Patients With Chronic Phase Ph+ CML
The US Food and Drug Administration (FDA) has approved Bosulif (bosutinib) for the treatment of patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic...
View ArticleClik here to view.
OS Benefits of TKIs Less Likely Among Lower-Income Patients With Ph+ CML
Among US patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), those with lower incomes have not derived the same benefits from therapeutic advances as those with higher...
View ArticleClik here to view.
Oncology Drug Coverage Determination Takes Months
Coverage determination for oncology drugs can be delayed for months after regulatory approval, according to research published in JAMA Oncology. Researchers found that coverage determination by...
View ArticleClik here to view.
Lower-Dose Ponatinib Appears Effective as Induction in Chronic Phase CML
Lower-dose ponatinib has demonstrated efficacy as induction in patients with chronic phase chronic myeloid leukemia (CML), according to research presented at the ASH Annual Meeting 2023. “[P]onatinib...
View ArticleClik here to view.
Olverembatinib Improves EFS in TKI-Resistant Chronic Phase CML
Olverembatinib can improve outcomes when compared to best available therapy (BAT) in patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML), according to...
View ArticleClik here to view.
TKI Discontinuation in Eligible CML Patients Could Save Billions of Dollars
A new study suggests that, if US patients with chronic myeloid leukemia (CML) discontinue tyrosine kinase inhibitor (TKI) treatment when eligible, more than $54 billion could be saved over the next 30...
View ArticleClik here to view.
Certain Cancers May Be More Common in Lesbian, Gay, and Bisexual Patients
The prevalence of certain cancers may be higher in lesbian, gay, and bisexual (LGB) patients than in heterosexual patients, according to data published in Cancer Causes & Control. Researchers found...
View ArticleClik here to view.
Increasing Doses May Improve Efficacy of COVID-19 Vaccines in Cancer Patients
After 3 or 4 doses, mRNA-based COVID-19 vaccines are similarly effective in reducing the risk of severe COVID-19 or hospitalization for patients with cancer and the general population, according to...
View ArticleClik here to view.
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown...
A randomized phase 2 trial examining the assignment of treatment based on gene-expression profiling compared with standard chemotherapy for patients with cancer of unknown primary site showed no...
View Article